Chimerix(US:CMRX)2020-02-25 15:30DSTAT in AML - DSTAT targets AML-implicated proteins and may improve chemotherapy and overall survival[8] - In a pilot study, 100% (11/11) of treatment-naïve primary AML patients achieved complete response (CR) with a single induction cycle of 7+3 chemotherapy plus DSTAT[9] - A randomized Phase 2B AML study showed a 70% CR/CRi rate in the high-dose DSTAT arm (14/20) compared to 68% in the control arm (13/19)[13] - Median time to neutrophil recovery was reduced by 17%, and platelet recovery by 20% with DSTAT[14] - Chimerix plans to initiate a Phase 3 trial for DSTAT in first-line AML in mid-2020[4, 42] BCV for Smallpox - Smallpox has approximately 30% mortality in unvaccinated populations[3] - BCV significantly reduced mortality in two animal models of orthopoxvirus infection[36] - In the mouse model, BCV treatment resulted in 78% survival compared to 13% in the placebo group[37] - In the rabbit model, BCV treatment resulted in 69% survival compared to 29% in the placebo group[37] - Chimerix is targeting an NDA filing with the US FDA for BCV in 2020 and anticipates potential BARDA stockpile procurement, with potential revenue of up to $100 million in 2021[4, 35, 42] Financial Position - Chimerix had $113.5 million in cash as of December 31[4]